Molecular Research on Drug Induced Liver Injury
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (31 March 2017) | Viewed by 73900
Special Issue Editors
Interests: alcoholic liver disease; alcoholic liver injury; alcohol metabolism; microsomal ethanol-oxidizing system; drug induced liver injury; herb induced liver injury; herbal traditional Chinese medicine (TCM); dietary supplements; causality assessment
Special Issues, Collections and Topics in MDPI journals
Interests: drug induced liver injury (DILI); hepatotoxicity causality assessment; Roussel Uclaf Causality Assessment (RUCAM); pharmacovigilance; drug hepatotoxicity; drug safety; adverse drug reactions
Special Issue Information
Dear Colleagues,
Drugs may cause liver injury in a few susceptible individuals, but the molecular events that lead to this idiosyncratic, dose independent and non-predictable drug induced liver injury (DILI) are mostly unknown since animal models to explore the pathogenetic mechanisms are not yet reliable. Little more is known about molecular events in connection with the intrinsic, dose dependent DILI since animal studies can clarify some questions of the underlying pathogenetic conditions. Molecular risk factors of idiosyncratic DILI include drug lipophilicity, high daily dose, and high metabolic rate, in addition to genetic factors that may initiate liver injury. Nevertheless, many pathogenetic challenges at the molecular level remain unknown. Uncertainties also relate to possible molecular diagnostic biomarkers, whether these could assist RUCAM (Roussel Uclaf Causality Assessing Method) to establish causality for suspected drugs in DILI cases. Clearly, much more research is still warranted to elucidate molecular pathogenetic events in DILI which may help to establish diagnostic biomarkers. The aim of this Special Issue is to provide a broad updated overview on these molecular related hepatotoxicity features with their challenges and highlights and to encourage more molecular research in DILI. We, therefore, asked experts in the field to contribute with their views to this emerging and fascinating topic of molecular aspects. Since some topics are still controversial, we expect and appreciate lively discussions, in addition to well-settled issues that are relevant to the clinical setting of molecular DILI and require balanced statements.
Prof. Dr. Rolf Teschke
Dr. Gaby Danan
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug induced liver injury (DILI)
- hepatotoxicity
- drug hepatotoxicity
- drugs
- drug lipophilicity
- drug metabolism
- daily drug dose
- RUCAM
- diagnostic biomarkers
- microRNA
- HLA
- molecular DILI pathophysiology
- molecules